Pieris - PIRS Stock Price

The market dynamics of Pieris Pharmaceuticals (PIRS) reflected in the price action indicate serious binary risks due to an over-reliance on a narrow range of respiratory treatments and the termination of several contracts. Meanwhile, the company relies on strategic alliances with industry leaders to develop oncology and respiratory drugs via the Anticalin system. The current metric stands at 152.42, while business development is based on the success of PRS-220 and payments from partners.

Price Performance Chart: Pieris Pharmaceuticals (PIRS) for 07/04/2022 - 11/14/2026

Pieris - analytical breakdowns and key metrics (PIRS)

- stock value and consensus price forecast:

Price Chart Pieris Pharmaceuticals|PIRS - Forecast Levels Chart

- issuer market value details:

Market Capitalization Pieris Pharmaceuticals, Inc.|PIRS - Company Buyout Price

- book capitalization information:

Net Assets per Single Share Pieris Pharmaceuticals|PIRS - Accounting Value of Company|Market Value to Book Value Ratio pieris.com|PIRS - Company Total Asset Base

- debt and liquidity details:

- company profitability and valuation multiples indicators:

PIRS - Net Income|Projected Future Earnings Pieris Pharmaceuticals|PIRS - P/E Multiple|Projected Price to Earnings Pieris|PIRS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals Inc|PIRS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Pieris Pharmaceuticals|PIRS - Earnings per share for the last four quarters|Quarterly EPS earnings growth pieris.com|PIRS - Earnings per share increase in current year|Earnings growth forecast for next year Pieris Pharmaceuticals

- sales volume and revenue information:

PIRS - Company Total Revenue|Company Projected Revenue Pieris Pharmaceuticals, Inc.|PIRS - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Pieris

Fundamental valuation:pieris.com

Signature product of Pieris Pharmaceuticals Inc

The market value of a share represents the discounted aggregate cash flow, reflecting the current investor consensus regarding the issuer's future profitability. By analyzing the market price action, one can assess the capitalization of Pieris Pharmaceuticals (PIRS), where quotes account for the efficiency of ESG standard integration into biopharmaceuticals and the rigor of ethical oversight for protein drug clinical trials.

Analysis of competing companies